Lock‑up agreements on RSUs for Avalo, Blaize and Ingram Micro expire in early July 2026

On July 5, 2026, the lock‑up periods governing certain restricted stock units (RSUs) issued by Avalo Therapeutics, Inc. and Blaize Holdings, Inc. came to an end, while Ingram Micro Holding Corporation’s comparable lock‑up concluded the day before. The expiration of these agreements removes a key restriction on the sale of those shares, a development that can affect liquidity, share price volatility, and the companies’ broader capital‑raising strategies.

Core developments

According to filings reported by marketscreener.com, specific RSUs issued by Avalo Therapeutics, Inc. were subject to a lock‑up agreement that expired on July 5, 2026. The same source notes an identical lock‑up end date for certain RSUs of Blaize Holdings, Inc. In a separate notice, marketscreener.com indicated that the lock‑up covering RSUs of Ingram Micro Holding Corporation ended on July 4, 2026.

These lock‑up agreements are contractual provisions that prevent the holders of the RSUs—typically executives, directors, or early investors—from selling the underlying shares for a predetermined period after issuance. The purpose is to align insiders’ interests with long‑term shareholder value and to avoid a sudden influx of shares that could depress the market price.

With the lock‑up periods now terminated, the RSU holders for each company are free to sell or otherwise transfer their shares, subject to any remaining insider‑trading policies or securities‑law reporting obligations.

Why it matters

Lock‑up expirations are closely watched by analysts and investors because they often precede a wave of insider selling that can increase trading volume and trigger short‑term price fluctuations. For Avalo Therapeutics, a biotech firm still navigating clinical‑stage development, any significant share sales could influence the perception of confidence among investors who are already sensitive to trial outcomes and regulatory milestones.

Blaize Holdings, a company focused on AI‑enabled automotive and edge‑computing platforms, has been positioning itself for strategic partnerships and potential acquisitions. The release of previously restricted shares may provide additional liquidity for employees who have been granted RSUs as part of compensation packages tied to product milestones.

Ingram Micro, a global technology distributor, completed its lock‑up a day earlier. The timing aligns with the company’s recent earnings release and its ongoing restructuring efforts, suggesting that the newly tradable shares could be used to support capital‑raising activities or to reward long‑term shareholders.

From a market‑structure perspective, the simultaneous expiration of lock‑ups across three unrelated firms underscores a broader trend: companies that went public or raised capital in the past few years often embed multi‑year RSU lock‑ups to stabilize early trading. Now that those periods are ending, the market may see a modest uptick in supply, which could modestly affect share price trajectories, especially for firms with relatively thin float.

Differing viewpoints and reactions

Public statements from the companies themselves were not included in the source material, and no analyst commentary was cited. Consequently, the immediate market reaction appears muted, with trading activity reflecting the standard post‑earnings and post‑lock‑up dynamics rather than any dramatic sell‑off.

Investors who monitor insider‑trading disclosures on the SEC’s Form 4 filings will likely keep a close eye on any subsequent transactions. In the absence of explicit guidance from Avalo, Blaize or Ingram Micro, market participants must infer intent from the volume and timing of any sales that occur after the lock‑up expiry.

What’s next

In the short term, the companies will need to manage the communication of any insider sales to avoid misinterpretation as a lack of confidence. Investor relations teams may issue press releases or conference‑call remarks to reassure shareholders that the unlock does not signal any change in strategic direction.

Analysts covering these stocks are expected to adjust their valuation models to reflect the increased share supply and potential changes in earnings per share calculations. For Avalo Therapeutics, the focus will remain on clinical progress; for Blaize Holdings, upcoming product launches and partnership announcements will dominate the narrative; for Ingram Micro, the emphasis will be on its distribution network performance and any capital‑raising moves.

Regulatory compliance will continue to be a priority. Even though the lock‑up agreements have expired, RSU holders must still comply with Rule 10b5‑1 trading plans, blackout periods, and other insider‑trading restrictions that remain in force.

Overall, the expiration of these lock‑up agreements marks a routine but noteworthy milestone in each company’s equity‑compensation timeline, one that could subtly reshape shareholder composition and market perception as the shares become fully tradable.